Zacks.com on MSN3h
Eyenovia Stock Tumbles on Termination of Phase III Myopia StudyEyenovia, Inc. EYEN announced the decision to terminate a phase III study evaluating its investigational drug-device product, ...
The failure of Eyenovia's CHAPERONE study has seen the company’s stock value drop drastically as it considers options and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback